Evidence map›Paper›PMID 19515279›Full record

ReviewCurrent neurology and neuroscience reports2009

What's new in dystonia?

Vicki Shanker, Susan B Bressman

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current neurology and neuroscience reports, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Vicki ShankerBeth Israel Medical Center, Albert Einstein College of Medicine, New York, NY 10003, USA. vshanker@chpnet.org
Susan B Bressman

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several advances have been made in dystonia in both the basic science and clinical realms. Recent research has implicated dysfunctional circuitry outside of the basal ganglia, thereby broadening our understanding of the pathophysiology of dystonia. Genetic achievements include the discovery of a genetic modifier that protects against clinical expression in DYT1 and the identification of the DYT6 gene (THAP1). Several reports provided expanded descriptions of the clinical features of dystonia and its associated symptoms. Follow-up studies of deep brain stimulation, typically targeting the globus pallidus internus, have been largely positive. The success of deep brain stimulation in many cases of generalized dystonia has led to trials in other forms of dystonia, such as medically refractive cervical dystonia. This article reviews relevant recent findings in dystonia.

Indexed as

DystoniaAge of OnsetAnti-Dyskinesia AgentsApoptosis Regulatory ProteinsBotulinum ToxinsDeep Brain StimulationDiagnosis, DifferentialDNA-Binding ProteinsHumansMolecular ChaperonesNuclear ProteinsSeverity of Illness IndexAnti-Dyskinesia AgentsApoptosis Regulatory ProteinsBotulinum ToxinsDNA-Binding ProteinsMolecular ChaperonesNuclear ProteinsTHAP1 protein, humanTOR1A protein, human

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.